Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

World's Largest TB Drug Maker Lupin Acquires German Generic Company Hormosan To Extend Reach Into Europe

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Lupin, the world's largest manufacturer of anti-TB drugs, has acquired German generics firm Hormosan Pharma GmbH to establish a "bridgehead" and sharpen its focus in the European market
Advertisement

Related Content

India’s Lupin Says Ready To Present Mandideep Plan To U.S. FDA; Push On Novel Drug Delivery, Biosimilars And Indian Market To Propel Revenue Growth
India’s Lupin Says Ready To Present Mandideep Plan To U.S. FDA; Push On Novel Drug Delivery, Biosimilars And Indian Market To Propel Revenue Growth
GSK Takes Lupin To Court To Block Generic Combivir Launch in the U.S.
GSK Takes Lupin To Court To Block Generic Combivir Launch in the U.S.
Lupin Looks “Down Under” For Generic Growth As Deal Spree Continues
Lupin Looks “Down Under” For Generic Growth As Deal Spree Continues
Lupin Deal Spree Continues, Looks ‘Down Under’ For Generic Growth
PharmAsia News India Pharma Roundup: Lupin, Strides Arcolab, GSK India, Nicholas Piramal, Jubilant
PharmAsia News India Pharma Roundup: Lupin, Strides Arcolab, GSK India, Nicholas Piramal, Jubilant
India’s Lupin Acquires Majority Stake In Japanese Generic Manufacturer Kyowa
Advertisement
UsernamePublicRestriction

Register

SC069193

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel